Impact of study design on vaccine effectiveness estimates of 2 mRNA COVID-19 vaccine doses in patients with stage 5 chronic kidney disease

Kyla L Naylor; Eric McArthur; Stephanie N Dixon; Jeffrey C Kwong; Doneal Thomas; Shabnam Balamchi; Peter G Blake; Amit X Garg; Mohammad Atiquzzaman; Michelle A Hladunewich; Adeera Levin; Angie Yeung; Matthew J Oliver

doi:10.1016/j.kint.2023.01.009

Impact of study design on vaccine effectiveness estimates of 2 mRNA COVID-19 vaccine doses in patients with stage 5 chronic kidney disease

Kidney Int. 2023 Apr;103(4):791-797. doi: 10.1016/j.kint.2023.01.009. Epub 2023 Jan 31.

Authors

Affiliations

¹ ICES, Toronto, Ontario, Canada; Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada; Lawson Health Research Institute and London Health Sciences Centre, London, Ontario, Canada.
² ICES, Toronto, Ontario, Canada; Lawson Health Research Institute and London Health Sciences Centre, London, Ontario, Canada.
³ ICES, Toronto, Ontario, Canada; Dalla Lana School of Public Health, Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada; Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada; Public Health Ontario, Toronto, Ontario, Canada; University Health Network, Toronto, Ontario, Canada.
⁴ Ontario Renal Network, Ontario Health, Toronto, Ontario, Canada.
⁵ Data and Decision Sciences, Ontario Health, Toronto, Ontario, Canada.
⁶ Lawson Health Research Institute and London Health Sciences Centre, London, Ontario, Canada; Ontario Renal Network, Ontario Health, Toronto, Ontario, Canada; Division of Nephrology, Western University, London, Ontario, Canada.
⁷ ICES, Toronto, Ontario, Canada; Department of Epidemiology & Biostatistics, Western University, London, Ontario, Canada; Lawson Health Research Institute and London Health Sciences Centre, London, Ontario, Canada; Division of Nephrology, Western University, London, Ontario, Canada.
⁸ British Columbia Renal, Vancouver, British Columbia, Canada.
⁹ Ontario Renal Network, Ontario Health, Toronto, Ontario, Canada; Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
¹⁰ British Columbia Renal, Vancouver, British Columbia, Canada; Department of Medicine, Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada; St. Paul's Hospital, Vancouver, British Columbia, Canada.
¹¹ Ontario Renal Network, Ontario Health, Toronto, Ontario, Canada; Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. Electronic address: matthew.oliver@sunnybrook.ca.

No abstract available

Keywords: CKD; COVID-19; methods; vaccine effectiveness.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
Kidney Failure, Chronic* / therapy
RNA, Messenger
Vaccine Efficacy

Substances

COVID-19 Vaccines
RNA, Messenger